Italia markets closed

FTSE MIB
33.922,16
+40,66(+0,12%)
Dow Jones
37.986,40
+211,02(+0,56%)
Nasdaq
15.282,01
-319,49(-2,05%)
Nikkei 225
37.068,35
-1.011,35(-2,66%)
Petrolio
83,25
+0,52(+0,63%)
Bitcoin EUR
60.181,45
+549,74(+0,92%)

Oramed Pharmaceuticals Inc. (ORMP)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.

Aggiungi a watchlist

2,2700

+0,0700

(+3,18%)

Alla chiusura: 04:00PM EDT

I prezzi di scambio non provengono da tutti i mercati

Capitalizzazione	91,979M
Beta (5 anni mensile)	1,82
Rapporto PE (ttm)	16,21
EPS (ttm)	0,1400
Prossima data utili	09 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	4,25

Tutte

GlobeNewswire
Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”). Pursuant to that certain Stock Purchase Agreement entered into on Septem
GlobeNewswire
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
PALO ALTO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. (Nasdaq: ORMP, “Oramed”) and Sorrento executed non